Sistema de Salut de Catalunya
Institut Català de la Salut
[Rivière A] Service de Pneumologie, Hôpital Avicenne (AP-HP), Université Sorbonne Paris Nord, Bobigny, France. [Picard C] Service de Transplantation Pulmonaire et Centre de Compétence de la Mucoviscidose, Hôpital Foch, Suresnes, France. [Berastegui C] Servei de Pneumologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Mora VM] Lung Transplant Unit, Department of Respiratory Medicine, H. Marqués de Valdecilla, Santander, Spain. [Bunel V] Service de Pneumologie, Hôpital Bichat (AP-HP), Paris, France. [Godinas L] Department of Respiratory Diseases, University Hospitals Leuven, Leuven, Belgium
Vall d'Hebron Barcelona Hospital Campus
2023-01-31T12:07:42Z
2023-01-31T12:07:42Z
2022-12
Connective tissue disease; Idiopathic inflammatory myopathy; Interstitial lung disease
Enfermedad del tejido conectivo; Miopatía inflamatoria idiopática; Enfermedad pulmonar intersticial
Malaltia del teixit conjuntiu; Miopatia inflamatòria idiopàtica; Malaltia pulmonar intersticial
In patients with interstitial lung disease (ILD) complicating classical or amyopathic idio-pathic inflammatory myopathy (IIM), lung transplantation outcomes might be affected by the disease and treatments. Here, our objective was to assess survival and prog-nostic factors in lung transplant recipients with IIM-ILD. We retrospectively reviewed data for 64 patients who underwent lung transplantation between 2009 and 2021 at 19 European centers. Patient survival was the primary outcome. At transplantation, the median age was 53 [46–59] years, 35 (55%) patients were male, 31 (48%) had clas-sical IIM, 25 (39%) had rapidly progressive ILD, and 21 (33%) were in a high- priority transplant allocation program. Survival rates after 1, 3, and 5 years were 78%, 73%, and 70%, respectively. During follow-up (median, 33 [7–63] months), 23% of patients developed chronic lung allograft dysfunction. Compared to amyopathic IIM, classical IIM was characterized by longer disease duration, higher-intensity immunosuppres-sion before transplantation, and significantly worse posttransplantation survival. Five (8%) patients had a clinical IIM relapse, with mild manifestations. No patient expe-rienced ILD recurrence in the allograft. Posttransplantation survival in IIM-ILD was similar to that in international all- cause- transplantation registries. The main factor as-sociated with worse survival was a history of muscle involvement (classical IIM). In lung transplant recipients with idiopathic inflammatory myopathy, survival was similar to that in all-cause transplantation and was worse in patients with muscle involvement compared to those with the amyopathic disease.
Article
Published version
English
Pulmons - Trasplantació; Pulmons - Malalties; Músculs - Malalties; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Surgical Procedures, Operative::Thoracic Surgical Procedures::Pulmonary Surgical Procedures::Lung Transplantation; DISEASES::Respiratory Tract Diseases::Lung Diseases::Lung Diseases, Interstitial; Other subheadings::Other subheadings::Other subheadings::/surgery; DISEASES::Nervous System Diseases::Neuromuscular Diseases::Muscular Diseases::Myositis; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::intervenciones quirúrgicas::procedimientos quirúrgicos torácicos::procedimientos quirúrgicos pulmonares::trasplante de pulmón; ENFERMEDADES::enfermedades respiratorias::enfermedades pulmonares::enfermedades pulmonares intersticiales; Otros calificadores::Otros calificadores::Otros calificadores::/cirugía; ENFERMEDADES::enfermedades del sistema nervioso::enfermedades neuromusculares::enfermedades musculares::miositis
Wiley
American Journal of Transplantation;22(12)
https://doi.org/10.1111/ajt.17177
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
Articles científics - HVH [3439]
